The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans
Lead sponsor
Asset
Avexitide
Listed sites
1
Recruiting sites
-
Estimated enrollment
80
Study population
-
Eligibility highlights
-
Primary endpoint
-
Registered trial locations
Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Who can enroll
Inclusion criteria
Exclusion criteria
1. Age < 25 or > 70 years (to avoid studying subjects who could have latent type 1 diabetes, or the effects of age extremes in subjects with normal or impaired fasting glucose).
2. CT genotype at rs7903146
3. HbA1c > 6.5%
4. Use of any glucose-lowering agents including metformin or sulfonylureas.
5. For female subjects: positive pregnancy test at the time of enrollment or study.
6. History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
7. Active systemic illness or malignancy.
8. Symptomatic macrovascular or microvascular disease.
Endpoints (0)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
No endpoints recorded for this trial.
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.